多发性骨髓瘤（MM）患者炎性细胞因子水平上升以及炎症在疾病发病机制中的作用最近被考虑。本研究的目的是定量评价粪液卡尔贝金（CP）作为一种非侵入性生物标志物用于多发性骨髓瘤患者炎症的评估。本研究是一项基于医院的病例对照研究。伊朗德黑兰省的医疗中心中被转诊的MM患者被识别并分为新的MM患者组（n = 40）和正在接受治疗的患者组（n = 28）。健康个体被纳入研究作为健康对照组（n = 25）。收集早晨的粪便样本并立即提取CP。在收集样本后，根据ELISA方法测量CP，并以μg / g粪便确定。大于50μg / g粪便的值为阳性并表明存在炎症。结果表明，在CP平均值方面，组之间存在显着差异（p = 0.001）。新病例、治疗中和对照组的CP均值分别为301.3（SD：141.0）、165.1（SD：153.9）和36.9（SD：13.5）。然后比较组之间的结果显示，新病例组与治疗组存在显着差异（p = 0.001），对照组与新病例组（p = 0.001）和治疗组（p = 0.001）也显示出显着差异，控制组的CP值明显低于其他两组。此外，研究结果显示，年龄和浆细胞与CP值存在显着相关性，随着年龄和浆细胞的增加，CP值也显著增加。结果表明，CP定量评价作为一种非侵入性实验室生物标志物，在多发性骨髓瘤患者中具有临床标记的高潜力，炎症应该被考虑为癌症的标志。建议进行进一步的诊断研究。版权所有：© 2023 Khosravi等。本文是在创作公共途径许可下发表的开放获取文章，允许在任何媒介上不受限制地使用、分发和复制，只要原作者和来源被证明。

Increased levels of inflammatory cytokines in multiple myeloma (MM) patients and the role of inflammation in disease pathogenesis, have recently been considered. The aim of this study was to quantitatively evaluation of fecal calprotectin (CP) as a non-invasive biomarker for the evaluation of inflammation in patients with multiple myeloma. This study is a hospital-based case control study. MM patients referred to patients referred to medical centers of Tehran province, Iran, were identified and classified into two groups of new MM patients (n = 40) and patients undergoing treatment (n = 28). Healthy individuals were included in the study as healthy control (n = 25). Morning stool samples were collected and CP was extracted immediately. After collecting the samples, CP was measured according to ELISA method and was determined in μg/g of feces. Values ​​above 50 μg/g of feces are positive and indicate inflammation. The results revealed that there is a significant difference between groups in terms if CP mean (p = 0.001). The mean of CP among new cases, under treatment and control groups were 301.3 (SD: 141.0), 165.1 (SD: 153.9) and 36.9 (SD: 13.5), respectively. Then the groups were compared in pairs, the results showed that the new case group was significantly different from the under-treatment group (p = 0.001), and also the control group showed a significant difference with the new case group (p = 0.001) and the under-treatment group (p = 0.001) that the amount of CP in the control group was significantly lower than the other two groups. In addition, the results of the study showed a significant correlation between age and plasma cells with CP value, so that with increasing age and plasma cells, CP value also showed a significant increase. The results indicate that quantitative evaluation of CP as a non-invasive laboratory biomarker has a high potential as a clinical marker in patients with multiple myeloma and inflammation should considered as a hallmark of cancer. Further diagnostic studies are recommended.Copyright: © 2023 Khosravi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.